CMMB Q2 2023 Earnings — Chemomab Therapeutics Ltd. Revenue & Financial Results | Market Cap Arena

CMMBChemomab Therapeutics Ltd.

$12M

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$15,818

Operating Income

-$8M

Net Income

-$8M

EPS (Diluted)

$-2.84

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$7M

Free Cash Flow

-$7M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$29M

Total Liabilities

$7M

Stockholders' Equity

$22M

Cash & Equivalents

$10M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$15,818	-$6M	+99.7%
Operating Income	-$8M	-$6M	-31.0%
Net Income	-$8M	-$6M	-28.8%